Diaminobutoxy-substituted isoflavonoid (DBI-1), a complex I inhibitor, has good synergy with the GLUT1 inhibitor BAY-876 to inhibit the survival of CRC cells both in vitro and in vivo [94]. This evidence concerns the gene SLC2A1 and colorectal carcinoma.